Historic Alzheimer’s Drug Infusion Marks Milestone in Canada

In a significant advancement for Alzheimer’s treatment in Canada, Sharon Runge has become the first patient in the country to receive an infusion of Lecanemab, a newly approved drug that targets the disease. This historic moment, facilitated by Health Canada, brings hope to many Canadians affected by Alzheimer’s.

Breakthrough Treatment Approved

Canada is the last of the G7 nations to approve Lecanemab, a monoclonal antibody designed to eliminate harmful amyloid plaques in the brain. Research indicates that this treatment can slow the progression of Alzheimer’s by approximately 30 percent. According to Dr. Sara Mitchell, a cognitive neurologist, the long-term data suggests that patients taking Lecanemab can experience up to four additional years of independent living.

As Alzheimer’s disease often leads to increased dependence on caregivers, the introduction of this drug is particularly meaningful for families. Dallard Runge, Sharon’s husband, expressed his optimism, stating, “My hope is that (the drug) delays the further onset of the disease for a while for us. The longer we have together, the more happiness we’ll get to share.”

Financial Barriers and Access Challenges

Despite the drug’s approval, Lecanemab has not yet received a funding recommendation from the Canada Drug Administration. Consequently, provincial health agencies have not provided coverage, leaving families like the Runges to bear the cost of treatment. The expense for biweekly infusions over a year can reach about $32,000, depending on the patient’s weight.

Dr. Mitchell emphasized the need for government support to ensure equal access to Lecanemab for all Canadians. “There are people that you’ll see every day on the street who have this disease and who want to keep living independently. That’s who this drug is for,” she stated.

Some public opposition exists regarding taxpayer funding of such an expensive drug. Responding to concerns, Dallard suggested that critics should “walk in our shoes,” reflecting the urgency and emotional weight of the situation. He expressed regret that Sharon could not have started the treatment sooner, noting her early symptoms appeared four years ago.

Medical experts emphasize the importance of early intervention in Alzheimer’s treatment. Research indicates that the troublesome proteins associated with the disease can accumulate in the brain decades before symptoms manifest. Future studies aim to determine whether Lecanemab can benefit asymptomatic patients who harbor these harmful plaques.

Moments before receiving her first infusion, Sharon shared her emotional journey with CTV National News, stating, “In my day-to-day life, I feel like I’m fine.” Although she has experienced declining short-term memory, she remains deeply connected to her family. “I’m so fortunate to have met him,” she said of Dallard, emphasizing that he is the most important person in her life.

The Runges now face the future with renewed hope, believing that this groundbreaking treatment may grant them more time together, a precious gift for any couple navigating the challenges of Alzheimer’s disease.